Wire · regulatory
US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 November 2026 · Fusion42 review
The US FDA has halted the Commissioner's National Priority Voucher program, a fast-track drug review initiative launched in 2025 to expedite approvals for therapies addressing urgent health needs. The program has faced criticism for its political appointee review council, potential political influence, and lack of new vouchers awarded since Commissioner Marty Makary left in May 2026.
This Wire brief sits within Fusion42's coverage of Drug Discovery, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You face fewer fast-track options from the FDA as a political review layer on drug approvals is removed. Adjust timelines and regulatory expectations now to avoid overreliance on accelerated pathways that are losing support.
◆ Coverage
2 sources · 12 Nov 2026
◆ Related on Wire
◆ Topics